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A series of twenty chalcone derivatives was synthetized and their anti-proliferative activity was 
tested against the human T-cell acute lymphoblastic leukemia-derived cell line (CCRF-CEM). 
Based on the structural features of the most active compounds a new library of chalcone derivatives, 
according to SAR design, was synthetized and their antiproliferative activity was tested on the same 
cancer cell line. Four of them (compounds 3, 4, 8, 28), based on lower IC50 values (between 6.1 and 
8.9 M), were selected for further investigation regarding the modulation of the protein expression 
of receptor for activated C kinase (RACK1), PKCα and PKCβ, and their action at cell cycle level. 
Cell cycle analysis indicated a block in G0/G1 phase for all four compounds, with a statistically 
significant decrease in the percentage of cells in S phase, with no indication of apoptosis (subG0/G1 
phase). Compounds 4 and 8 showed a statistical significant reduction in the expression of PKCα 
and an increase in PKCβ, which together with the demonstration of an antiproliferative role of 
PKCβ as assessed by treating cells with a selective PKCβ activator, indicated that the 
antiproliferative effect observed is likely to be mediated through PKCβ induction.  
 
1. Introduction 
Chalcones are natural occurring compounds produced by plants, precursors of flavonoids, including 
in their structure two aromatic rings joined by an α,β-unsaturated carbonyl system (Figure 1). They 
have been exploited for wide application in pharmacological area, due to their diverse biological 
activities, such as antimicrobial, antibacterial, antifungal, anti-inflammatory, anti-nociceptive 
properties as well as antitumor activity observed in different types of cancer, including leukemia, 




Figure 1. General structure of chalcone and synthesized derivatives. 
 
 
Cancer is matter of concern in medicinal chemistry, and an increasing burden to the population, 
where the deaths from cancer worldwide are projected to reach over 13 million in 2030 (World 
Health Organization, https://www.who.int/cancer/resources/keyfacts/en/ visited Jan 8, 2020). The 
new generations of anticancer drugs are designed to target signals that promote or regulate the cell 
cycle, growth factors or their receptors, pathways affecting DNA repair and cell death rather than 
targeting directly DNA synthesis.[2] Many different cellular targets of chalcones have been 
highlights in cancer cells, as repressing Aurora Kinase A gene (AURKA) in breast cancer[3] or 
reveling their potential reversal activity against P-gp-mediated MDR, involved in resistance 
mechanism,[4, 5] (as inducing poly-ADP-ribose polymerase cleavage and stabilizing p53 in a dose-
dependent manner in colorectal carcinoma.[6] Recently, chalcone derivatives were shown to inhibit 
Notch signaling in CCRF-CEM.[7, 8]  
T-Acute lymphoblastic leukemia (ALL) is one of the most aggressive blood cancer, which account 
for approximately 15% of pediatric and 25% of adult acute lymphoblastic leukemia, in most cases 
curable.[9] However, chemotherapy resistance occurred in patients with T-ALL, leading to treatment 
failure and early relapse, and the causes of the occurrence of this resistance are not completely 
elucidated.[10] In a recent study, it has been shown that the overexpression of the receptor of 
activated C kinase 1 (RACK1) was responsible for chemotherapy resistance of T-cell acute 
lymphoblastic leukemia (T-ALL) increasing the activity of isoform α of protein kinase C (PKCα), 
which lead to a reduction in the level of Apaf-1, caspase 3 and FEM1b.[11]  
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RACK1 has been identified in the early nineties and so named because of its interaction with 
Protein Kinase C (PKC).[12] RACK1 is now recognized as a multiple target scaffolding protein 
involved in several key biological events, including development, immune response, neuronal 
activity, and cancer.[13, 14] Due to its plethora of interaction proteins, RACK1 controls essential 
cellular processes, such as transcription and translation, cell proliferation and growth as well as cell 
spreading and cell-cell interactions.[13] Regarding PKC, RACK1 could serve as a receptor for 
activated PKCβ and other PKC isoforms, including PKCδ and PKCμ. The binding of RACK1 to 
PKC leads to an increase in kinase activity, and to shuttle activated PKC to its correct cellular 
location. As early recognized, PKC activity and/or modulation of its isoenzyme expression has been 
implicated in the regulation, both increase and decrease, of malignant cell proliferation, apoptosis, 
tumor invasiveness, and resistance phenotype.[15-18] It is currently recognized that PKC isoforms 
have a complex not univocal role in cancer, meaning that they can have both detrimental or 
protective roles depending on the type of tumor considered, and therefore the use of PKC 
modulators must be done with caution taking into account the specific role of the different isoforms 
in the different tumors. Many PKC inhibitors have indeed entered clinical trials but has so far 
yielded very limited success, and in light of the fact that more recent studies demonstrated that PKC 
can also function as tumor suppressors, future clinical efforts should focus on restoring, rather than 
inhibiting, PKC activity.[19] Similarly to PKC, also RACK1 aberrant expression, pro- or anti-
oncogenic effects, and contribution to the various stages of cell migration and invasion has been 
described in various cancers.[14, 20, 21]  
Continuing our research in the synthesis of anticancer compounds,[22-29] the aim of this work was 
the synthesis of chalcone derivatives containing electron-withdrawing or electron-donating 
substituents on both the aromatic rings, and the evaluation of their antiproliferative effects, and 
possible modulation of PKC and RACK1 expression in the human T-cell acute lymphoblastic 
leukemia-derived cell line CCRF-CEM.  
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2. Results and discussion 
2.1. Chemistry 
Chalcone derivatives were synthesized using the synthetic methodology previously described.[30, 31] 
Briefly, an aqueous solution of sodium hydroxide was added slowly to a methanol solution of the 
appropriate acetophenone. After the solution was cooled to room temperature, the appropriate 
benzaldehyde was added. The mixture was stirred at room temperature overnight to provide the 
corresponding chalcones in good yields (Table 1 and Table 2). The synthesis of products is easy to 
achieve with good grade of purity. On the contrary, in our hands, and also searching the literature 
data, the chalcone derivative with a p-NO2 group on ring A was not able to be synthesized. All the 
products were characterized by NMR analysis, in which the presence of the olefinic double bond 
protons have a coupling constant J of 15.6 Hz confirming the trans stereochemistry. 
 
2.2. Biological activity 
The antiproliferative effects of the first library of the chalcone derivates 1–20 was evaluated in 
CCRF-CEM cells, a T lymphoblasts (T-ALL) from a 4 yrs old female isolated in 1964. For this 
blood tumor cell line a duplication time of approximately 24 h has been reported.[32] Cells were 
treated for 72 h, allowing three cell cycles, with increasing non-cytotoxic concentrations of the 
synthetized chalcones (0.16, 0.8, 4, 20 and 100 M) or DMSO as vehicle control. The absence of 
cytotoxicity was assessed by lactate dehydrogenase leakage in a preliminary experiment testing 
compounds at 100 M (data not shown). After 72 h, cell numbers were counted at the Coulter 
Counter, and the IC50 values calculated by linear regression analysis of data (IC50 is the 
concentration resulting in 50% inhibition of cell proliferation) and the results are presented in Table 
1.  











 IC50 (μM) 
1 o-F H > 30 11 p-Me p-Cl > 30 
2 o,p-Cl2 H > 30 12 p-Me p-Ph > 30 
3 m-NO2 H 8.9±1.2 13 p-Me p-Me > 30 
4 o-CF3 H 7.5±1.4 14 p-Me p-OMe > 30 
5 p-OMe H 7.9±1.2 15 p-Me p-NO2 > 30 
6 2-naphthyl H > 30 16 p-OMe p-Me > 30 
7 H p-Me > 30 17 p-OBn p-Me > 30 
8 H m-NO2 6.1±1.1 18 m-NO2 p-Me > 30 
9 H o-OMe 6.8±1.1 19 p-OMe m-NO2 > 30 
10 p-Me p-Br > 30 20 p-Cl p-OMe > 30 
Cells were treated for 72 h with increasing non-cytotoxic concentrations of the synthetic chalcones. 
Cell proliferation was assessed by cell counting at the Coulter Counter. The IC50 (M) values were 
calculated by linear regression analysis of data in three independent experiments. IC50 is reported as 
mean±SD.  
 
Based on the results of the aforementioned screening and considering the antiproliferative activity 
of compounds 3, 4, 5, 8 and 9, which showed the lowest IC50 values (from 6.1 to 8.9 M), a second 
library of chalcone derivatives was created, compounds 21 – 32, based on the presence of the same 
electron-withdrawing or electron-donating substituents of compounds 3, 4, 5, 8 and 9 on the 
aromatic rings. This second library will elucidate the importance of the single substituent in the 
antiproliferative activity based on structure-activity relationships. The antiproliferative activity of 
the new library against CCRF-CEM cells is presented in Table 2. The partition coefficient, 
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calculated for all the new compounds and for 3, 4, 5, 8 and 9 showed good values for almost all of 
them. 
 










 IC50 (μM) LogP 
21 o-NO2 H 44.7±22.9 4.33 27 H o-NO2 14.7±0.5 3.41 
3 m-NO2 H 8.9±1.2 4.57 8 H m-NO2 6.1±1.1 5.19 
22 p-NO2 H 26.2±20.1 3.82 28 H o-CF3 11.4±2.2 4.87 
4 o-CF3 H 7.5±1.4 6.29 29 H m-CF3 14.8±3.2 5.9 
23 m-CF3 H 14.0±2.2 6.48 30 H p-CF3 49.5±21.0 5.7 
24 p-CF3 H 15.3±1.2 5.69 9 H o-OMe 6.8± 1.1 4.58 
25 o-OMe H 13.7±1.7 4.48 31 H m-OMe 14.0±3.7 5.26 
26 m-OMe H 27.1±1.8 5.03 32 H p-OMe 20.4±9.4 3.99 
5 p-OMe H 7.9±1.2 4.51  
Cells were treated for 72 h with increasing non-cytotoxic concentrations of the synthetic chalcones. 
Cell proliferation was assessed by cell counting at the Coulter Counter. The IC50 (M) values were 
calculated by linear regression analysis of data in three independent experiments. IC50 is reported as 
mean±SD.  
 
The new SAR experiments showed that for the lower IC50 values the presence of the NO2 on the 
meta position, CF3 on the ortho position and the OMe group on the para position (compounds 3, 4 
and 5 respectively) as R1 substituents and the NO2 on the meta position , the CF3 on the ortho 
position and the OMe group on the ortho position (compounds 8, 28 and 9 respectively) as R2 
substituents and mandatory for the highest inhibition. 
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From the new library we considered chalcones 3, 4 and 8, 28 respectively which contain the same 
substituents with resonance or inductive electron-withdrawing effect at the same positions but on 
the opposite aromatic rings. These compounds were chosen for further analyses with the aim to 
investigate the mechanism underlying their antiproliferative effects.  
Next, we investigated the effect of the selected compounds on the cell cycle. Cell cycle was 
evaluated by flow cytometry, assessing cellular DNA content following cell staining with 
propidium iodide and deconvolution of the cellular DNA content frequency histograms,[33] which 
allow to investigate distribution of cells in three major phases of the cycle (G0/G1 vs S vs G2/M) 
and makes it possible to detect apoptotic cells with fractional DNA content (pre-G0). Results are 
presented in Figure 2. Consistent with the lack of cytotoxicity, no increase in % of pre-G0 cells was 
observed, (Figure 2A), while an arrest in G0/G1 was observed for all selected compounds, 
characterized by a statistically significant increase in the % of cells in G0/G1 phase (Figure 2B) and 
a concomitant reduction of the cells in the S phase (Figure 2C). Results of the cell cycle analysis are 





Figure 2. Cell cycle analysis following 72 h of treatment with the selected compounds in CCRF-
CEM. Cells were treated for 72 with the selected compounds tested at the IC50 values or with 
DMSO as vehicle control. Cells were fixed and processed according to PI staining protocol listed in 
the Materials and Methods section. 30,000 cells were analyzed using flow cytometer. Cell cycle 
analysis calculated pre-G0, G0/G1, S and G2 phases from PI histograms. Each value represents 
mean±SD of three independent experiments. Statistical analysis was performed by ANOVA 
followed by Dunnett’s multiple comparison test with *p<0.05 and **p < 0.01 versus control cells.  
 
In CCRF-CEM the involvement of RACK1/PKC in chemotherapy resistance has been described.[11, 
17] This together, with the role of RACK1/PKC in cancer,[14, 19] led us to investigate the effect of 
compounds 3, 4, 8 and 28 on the protein expression of PKC, PKC and RACK1, and the role of 
PKC in cell proliferation by using the selective activator Pseudo RACK1. For protein expression, 
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compounds were tested at the IC50 values for 48 h. This early time point was chosen to see if 
changes in the expression levels occurred before the time point of 72 h used to assess the 
antiproliferative effect. The effect of Pseudo RACK1 on cell proliferation was evaluated at 72 h. 
Results are shown in Figure 3. A statistical significant decrease in PKC expression was observed 
for compounds 4 and 8 (Figure 3A), while an increase in PKC expression was observed for 
compounds 3, 4, 8, and no changes in RACK1 for all four compounds, indicating a selective action 
rather than an unspecific effect on protein synthesis. To understand the possible implication of the 
increased expression of PKC, Pseudo RACK1, a peptide which has been demonstrated both in 
vitro and in vivo to bind and activate PKC in the absence of PKC activators,[34] was used. Cells 
were treated for 72 h with increasing concentration of Pseudo RACK1, and cells counted at the end 
of the experiment (Figure 3D). A dose-dependent inhibition of cell proliferation was observed, 
suggesting that the increase in PKC induced by compounds 3, 4, 8 may probably explain the 
observed decrease in cell proliferation. The significance of the reduction of PKC expression 
requires further studies, but consistent with the data published[11] a possible hypothesis could be a 





Figure 3. Effect of the selected chalcone derivatives on the  and  isoforms of PKC, RACK1 
expression and antiproliferative effect of PKC activation in CCRF-CEM. A, B, C. Effect on PKC 
(A), PKC (B) and RACK1 protein expression. Cells were treated for 48 h with the compounds 28, 
3, 4, 8 at the IC50 values or DMSO as vehicle control. β-tubulin expression was used to normalize 
expression. The image is a representative western blot. Each value represents the mean ± SD, n=3 
independent experiments. Statistical analysis was performed with Dunnett’s multiple comparison 
test with *p<0.05, ** p<0.01 versus control (Cont). D. Effect of PKC activation on CCRF-CEM 
proliferation. Cells were treated for 72 h with increasing concentrations of pseudo RACK1 (0.5-1.5 
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M), a selective peptide activator of PKC. Cell proliferation was assessed by cell counting at the 
Coulter Counter. Each value represents the mean ± SD, n=3 independent experiments. Statistical 




The preparation of two different libraries of chalcone derivatives, the first for an initial screening 
and the second for a structure-activity relationship identification, bearing electron-withdrawing or 
electron-donating substituents is described and the compounds were tested for their antiproliferative 
activity against CCRF-CEM cells. From the first screening, compounds 3, 4, 5, 8 and 9, which 
showed the highest antiproliferative activity were selected as lead compounds for the synthesis of 
the second library. After the second screening, chalcones 3, 4, 8 and 28 bearing electron-
withdrawing substituents at the same positions but on the opposite aromatic rings, were chosen for 
further investigation. Cell cycle analysis of these compounds demonstrated a cytostatic effect, rather 
than induction of apoptosis. Moreover, regarding the protein expression of PKCa, PKCβ and 
RACK1, a significant decrease in PKC expression was observed for compounds 4 and 8, while an 
increase in PKC expression was detected for compounds 3, 4 and 8. Although, no changes in 
RACK1 for all four compounds was discovered suggesting a selective action rather than an effect 
on the protein synthesis. A dose-dependent inhibition of the cell proliferation with the peptide 
PseudoRACK1 suggested that the increase in PKC induced by compounds 3, 4 and 8 could 
explain the decrease in cell proliferation. Even if further experiments are needed to better 
characterize the effect on PKC isoforms, the mechanisms underlying the modulatory effects 
observed, i.e. pre- or post-transcriptional effect, and their implication in term multidrug resistance 
compounds 4 and 8 have been identified as candidates for further investigation and development as 
additional therapeutic option in T-cell acute lymphoblastic leukemia. 
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4. Experimental section  
4.1. General procedures 
 All reactions were monitored by TLC on silica gel, with detection by UV light (254 nm). 1H NMR 
and 13C NMR spectra were recorded with Varian Oxford 300 MHz spectrometer at 300 and 75 MHz 
respectively. MS analyses were performed by using a Thermo Finnigan (MA, USA) LCQ 
Advantage system MS spectrometer with an electrospray ionization source and an ‘Ion Trap’ mass 
analyzer. The MS spectra were obtained by direct infusion of a sample solution in MeOH under 
ionization, ESI positive. 
 
4.2. General Procedure for the synthesis of α,β-unsaturated ketones 
To a methanol solution (30 mL) of acetophenone (5.0 mmol) an aqueous solution of potassium 
hydroxide (5 %, 25 mL) was slowly added at 0°C. The appropriate benzaldehyde (6.0 mmol) was 
added and the new solution was stirred overnight at the room temperature. The resulting solution 
was evaporated in vacuum, EtOAc was added and the organic phase was washed with water and 
brine, dried with Na2SO4, filtered and evaporated. The desired product was obtained after 
purification by flash column chromatography.[30] 
4.2.1 (E)-3-(2-Nitrophenyl)-1-phenylprop-2-en-1-one (21): 1H NMR (300 MHz, CDCl3) δ = 8.24-
8.15 (m, 4H), 7.88 (d, J= 6.0 Hz, 1H), 7.84-7.82 (m, 1H), 7.76-7.71 (m, 1H), 7.56-7.47 (m, 4H) 
ppm. 13C NMR (75 MHz, CDCl3) δ = 188.13, 157.34, 148.30, 139.69, 136.71, 129.75, 129.61, 
129.28, 128.80, 127.55, 127.42, 127.17, 126.24, 118.96 ppm. MS (ESI) for C15H11NO3: m/z 254.37 
[M+H]+. 
4.2.2. (E)-3-(3-Nitrophenyl)-1-phenylprop-2-en-1-one (3): 1H NMR (300 MHz, CDCl3) δ = 8.49 
(s, 1H), 8.23 (d, J=9.0 Hz, 1H), 8.03 (d, J= 8.4 Hz, 2H), 7.92 (d, J=9.0 Hz, 1H), 7.84-7.79 (m, 1H), 
7.67-7.50 (m, 5H) ppm. 13C NMR (75 MHz, CDCl3) δ = 189.58, 141.56, 137.56, 136.65, 134.24, 
133.26, 130.70, 130.01, 128.77, 128.56, 124.61, 122.33 ppm. MS (ESI) for C15H11NO3: m/z 254.61 
[M+H]+. 
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4.2.3. (E)-3-(4-Nitrophenyl)-1-phenylprop-2-en-1-one (22): 1H NMR (300 MHz, CDCl3) δ = 8.28 
(d, J=9.0 Hz, 2H), 8.03 (d, J=9.0 Hz, 2H), 7.80 (d, J=2.4 Hz, 2H), 7.78 (s, 1H), 7.67 (s, 1H), 7.63-
7.51 (m, 3H) ppm. 13C NMR (75 MHz, CDCl3) δ = 188.85, 142.16, 137.33, 136.47, 133.98, 132.85, 
130.96, 129.08, 128.52, 127.86, 123.88, 122.12 ppm. MS (ESI) for C15H11NO3: m/z 254.48 [M+H]
+. 
4.2.4. (E)-1-Phenyl-3-[2-(trifluoromethyl)phenyl]prop-2-en-1-one (4): 1H NMR (300 MHz, 
CDCl3) δ = 8.14 (dd, J=2.1 Hz, 15.6 Hz 1H), 8.03-7.95 (m, 2H), 7.82 (d, J=7.8 Hz, 1H), 7.73 (d, 
J=7.8 Hz, 1H), 7.63-7.58 (m, 2H), 7.54-7.48 (m, 3H), 7.43 (d, J=15.6 Hz, 1H) ppm. 13C NMR (75 
MHz, CDCl3) δ = 190.28, 140.18, 140.16, 137.66, 134.03, 132.99, 132.06, 129.63, 129.42, 129.01, 
128.64, 127.93, 126.62, 126.35, 126.28, 126.20, 126.13, 125.75, 122.12 ppm. MS (ESI) for 
C16H11F3O: m/z 277.08 [M+H]
+. 
4.2.5. (E)-1-Phenyl-3-[3-(trifluoromethyl)phenyl]prop-2-en-1-one (23): 1H NMR (300 MHz, 
CDCl3) δ = 8.04 (d, J=7.2 Hz, 2H), 7.89-7.79 (m, 3H), 7.68-7.50 (m, 6H) ppm. 13C NMR (75 MHz, 
CDCl3) δ = 189.96, 142.74, 137.82, 135.72, 133.03, 131.74, 131.54, 131.31, 129.48, 128.69, 128.52, 
126.83, 126.78, 126.73, 126.69, 125.59, 124.73, 124.68, 124.63, 124.58, 123.73, 121.98 ppm. MS 
(ESI) for C16H11F3O: m/z 277.44 [M+H]
+. 
4.2.6. (E)-1-Phenyl-3-[3-(trifluoromethyl)phenyl]prop-2-en-1-one (24): 1H NMR (300 MHz, 
CDCl3) δ = 8.28 (d, J=9.0 Hz, 2H), 8.05-8.02 (m, 2H), 7.80-7.78 (m, 2H), 7.67 (s, 1H), 7.63-7.60 
(m, 1H), 7.56-7.51 (m, 3H) ppm. 13C NMR (75 MHz, CDCl3) δ = 188.21, 149.98, 139.94, 136.62, 
133.54, 131.89, 131.06, 128.14, 128.02, 127.92, 127.64, 126.89, 126.55, 126.13, 126.09, 125.99, 
125.93, 125.01, 121.87 ppm. MS (ESI) for C16H11F3O: m/z 277.36 [M+H]
+. 
4.2.7. (E)-3-(2-Methoxyphenyl)-1-phenylprop-2-en-1-one (25): 1H NMR (300 MHz, CDCl3) δ 
=8.10 (d, J=15.9 Hz, 1H), 7.90  (d, J=7.3 Hz, 2H), 7.83 (d, J=7.6 Hz, 1H), 7.75-7.68 (m, 1H), 7.55-
7.48 (m, 2H), 7.41-7.31 (m, 3H), 7.23 (d, J=15.7 Hz, 1H), 3.86 (s, 3H) ppm. 13C NMR (75 MHz, 
CDCl3) δ = 188.55, 157.12, 143.56, 137.19, 137.16, 135.66, 131.86, 131.13, 129.56, 128.18, 121.99, 
121.00, 115.91, 112.87, 54.93 ppm. MS (ESI) for C16H14O2: m/z 239.41 [M+H]
+. 
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4.2.8. (E)-3-(3-Methoxyphenyl)-1-phenylprop-2-en-1-one (26): 1H NMR (300 MHz, CDCl3) δ 
=8.03 (d, J=6.9 Hz, 2H), 7.78 (d, J=15.9 Hz, 1H), 7.54-7.46 (m, 4H), 7.35-7.30 (m, 1H), 7.25-7.23 
(m, 1H), 7.16 (t, J=1.5 Hz, 1H), 6.98-6.94 (m, 1H), 3.84 (s, 3H) ppm. 13C NMR (75 MHz, CDCl3) δ 
= 190.47, 159.96, 144.70, 138.19, 136.27, 132.76, 129.93, 128.60, 128.49, 122.41, 121.07, 116.29, 
113.47, 55.32 ppm. MS (ESI) for C16H14O2: m/z 239.19 [M+H]
+. 
4.2.9. (E)-3-(4-Methoxyphenyl)-1-phenylprop-2-en-1-one (5): 1H NMR (300 MHz, CDCl3) δ = 
8.01 (d, J=8.1 Hz, 2H), 7.79 (d, J=15.9 Hz, 1H), 7.62-7.47 (m, 5H), 7.41 (d, J=15.6 Hz, 1H), 6.93 
(d, J=8.7 Hz, 2H), 3.85 (s, 3H) ppm. 13C NMR (75 MHz, CDCl3) δ = 190.55, 161.68, 144.65, 
138.53, 132.49, 130.18, 129.04, 128.52, 128.38, 128.00, 127.64, 119.85, 114.42, 113.61, 55.62 ppm. 
MS (ESI) for C16H14O2: m/z 239.33 [M+H]
+. 
4.2.10. (E)-1-(2-Nitrophenyl)-3-phenylprop-2-en-1-one (27): 1H NMR (300 MHz, CDCl3) δ = 
8.18 (d, J=9.3 Hz, 1H), 7.76 (t, J=8.7 Hz, 1H), 7.65 (t, J=8.1 Hz, 1H), 7.52-7.48 (m, 3H), 7.41-7.37 
(m, 3H), 7.25 (d, J=16.2 Hz, 1H), 7.00 (d, J=16.2 Hz, 1H) ppm. 13C NMR (75 MHz, CDCl3) δ = 
192.83, 146.25, 136.31, 133.98, 133.95, 131.02, 130.56, 128.98, 128.79, 128.67, 128.52, 126.25, 
124.51 ppm. MS (ESI) for C15H11NO3: m/z 254.56 [M+H]
+. 
4.2.11. (E)-1-(3-Nitrophenyl)-3-phenylprop-2-en-1-one (8): 1H NMR (300 MHz, CDCl3) δ = 8.83 
(s, 1H), 8.38 (dd, J=8.1 Hz, 27.6 Hz, 2H), 7.89 (d, J=15.6 Hz, 1H), 7.74, 7.66-7.56 (m, 3H), 7.51 (d, 
J=15.6 Hz, 1H), 7.46-7.44 (m, 3H). 13C NMR (75 MHz, CDCl3) δ = 187.97, 148.43, 146.73, 139.51, 
134.31, 134.04, 131.17, 129.88, 129.08, 128.71, 127.01, 123.23, 120.68. MS (ESI) for C15H11NO3: 
m/z 254.43 [M+H]+. 
4.2.12. (E)-3-Phenyl-1-[2-(trifluoromethyl)phenyl]prop-2-en-1-one (28): 1H NMR (300 MHz, 
CDCl3) δ= 7.97 (d, J= 8.9 Hz,1H), 7.58 (t, J= 7.4 Hz,1H), 7.55-7.53 (m, 1H), 7.50 (dd, J= 2.0 Hz, 
7.5 Hz, 2H), 7.43 (d, J= 7.6 Hz, 1H), 7.40-7.35 (m, 3H), 7.31(d, J= 15.6 Hz, 1H), 7.02 (d, J= 15.4 
Hz, 1H) ppm. 13C NMR (75 MHz, DMSO) δ = 187.89, 146.12, 138.93, 138.51, 137.66, 135.05, 
133.12, 131.67, 130.85, 130.03, 129.85, 129.66, 129.43, 129.12, 129.03, 128.88, 127.56, 125.13, 
125.00, 122.02 ppm. MS (ESI) for C16H11F3O: m/z 277.17 [M+H]
+. 
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4.2.13. (E)-3-Phenyl-1-[3-(trifluoromethyl)phenyl]prop-2-en-1-one (29): 1H NMR (300 MHz, 
CDCl3) δ = 8.26 (s, 1H), 8.20 (d, J= 7.8 Hz, 1H), 7.89-7.84 (m, 2H), 7.69-7.64 (m, 2H), 7.51 (d, J= 
15.6 Hz, 1H), 7.45-7.44 (m, 2H), 7.23-7.14 (m, 2H) ppm. 13C NMR (75 MHz, DMSO) δ = 188.89, 
145.56, 139.33, 138.73, 137.36, 134.95, 132.93, 131.33, 130.55, 129.93, 129.90, 129.85, 129.58, 
129.34, 128.70, 128.20, 127.06, 125.35, 125.30, 122.07 ppm. MS (ESI) for C16H11F3O: m/z 277.31 
[M+H]+. 
4.2.14. (E)-3-Phenyl-1-[4-(trifluoromethyl)phenyl]prop-2-en-1-one (30): 1H NMR (300 MHz, 
CDCl3) δ = 8.78-8.73 (m, 2H), 8.13 (d, J= 8.1 Hz, 2H), 7.54-7.40 (m, 3H), 7.25 (d, J= 7.8 Hz, 2H) 
ppm. 13C NMR (75 MHz, CDCl3) δ = 187.51, 143.82, 139.92, 137.72, 134.15, 131.89, 131.56, 
127.94, 127.02, 127.00, 126.84, 125.94, 125.65, 125.82, 125.01, 124.99, 124.83, 124.06, 122.12 
ppm. MS (ESI) for C16H11F3O: m/z 277.54 [M+H]
+. 
4.2.15. (E)-1-(2-Methoxyphenyl)-3-phenylprop-2-en-1-one (9): 1H NMR (300 MHz, CDCl3) δ = 
7.82 (d, J= 15.5 Hz, 1H),  7.65 (dd, J= 2.0 Hz, 7.5 Hz, 1H), 7.58–7.55 (m, 2H), 7.48–7.44 (m, 1H), 
7.38–7.33 (m, 4H), 7.04-7.01 (m, 1H) 6.98–6.93 (m, 1H), 3.86 (s, 3H) ppm. 13C NMR (75 MHz, 
CDCl3) δ = 189.43, 156.97, 143.58, 138.18, 137.65, 136.44, 131.99, 131.76, 129.88, 128.10, 122.14, 
121.14, 116.27, 112.76, 55.32 ppm. MS (ESI) for C16H14O2: m/z 239.34 [M+H]
+ 
4.2.16. (E)-1-(3-Methoxyphenyl)-3-phenylprop-2-en-1-one (31): 1H NMR (300 MHz, CDCl3) δ = 
8.03 (d, J= 15.6 Hz, 1H), 7.65–7.62 (m, 2H), 7.59 (dd, J= 1.8 Hz, 7.5 Hz, 1H), 7.56–7.54 (m, 1H), 
7.52 (d, J= 15.6 Hz, 1H), 7.42–7.38 (m, 4H), 7.14 (dd, J= 3.0 Hz, 8.4 Hz), 3.85 (s, 3H) ppm. 13C 
NMR (75 MHz, CDCl3) δ = 189.72, 159.88, 143.87, 138.02, 136.83, 133.07, 129.98, 128.73, 
128.05, 123.41, 122.14, 116.55, 114.71, 54.97. MS (ESI) for C16H14O2: m/z 239.45 [M+H]
+. 
4.2.17. (E)-1-(4-Methoxyphenyl)-3-phenylprop-2-en-1-one (32): 1H NMR (300 MHz, CDCl3) δ = 
8.05–8.02 (m, 2H), 7.78 (d, J= 15.6 Hz, 1H), 7.65–7.61 (m, 2H), 7.53(d, J= 15.6 Hz, 1H), 7.44-7.39 
(m, 3H), 6.98–6.96 (m, 2H), 3.83 (s, 3H) ppm. 13C NMR (75 MHz, CDCl3) δ = 189.12, 162.73, 
145.87, 139.77, 133.12, 131.85, 129.65, 129.01, 128.77, 128.45, 127.93, 118.85, 114.32, 113.87, 




4.3. Log Pow determination 
RP-HPLC analysis were performed to correlate the hydrophobicity of the compounds with their 
retention time. The chromatograms were registered using Partisil C18-ODS reversed-phase HPLC 
column at 25 °C and water/acetonitrile (50:50) as mobile phase with KI as internal standard (flow 
rate: 1 mL/min; λ= 254 nm). The calibration curve was realized in comparison with reference 




For all experiments the CCRF-CEM cell line was used (CEM/C1, ATCC CRL-2265TM, gift form 
Luca Mazzarella, European Institute of Oncology, Department of Experimental Oncology, Milan, 
Italy). Cells were seeded at a density of 6x105 cells/ml in RPMI 1640 containing 2 mM l-glutamine, 
0.1 mg/ml streptomycin, 100 IU/ml penicillin and 0.1% gentamycin, supplemented with 10% 
heated-inactivated fetal calf serum (media) and cultured at 37°C in 5% CO2 for 48 h for western 
blot analysis (3 ml per sample) and for 72 h for cell proliferation or cell cycle analysis (1 ml per 
sample). Cell culture media and all supplements were from Sigma-Aldrich Co. (St. Louis, Mo, 
USA). 50 mM stock solutions were prepared for each compound in dimethyl sulfoxide (DMSO). 
DMSO was used as vehicle control in all experiments (0.1% final concentration in culture medium). 
Pseudo RACK1 activator of protein kinase C (pseudo RACK) was obtained from Tocris 
Bioscience (Bristol, UK). The pseudosubstrate consists of peptide derived from the C2 domain of 
PKC linked by a disulfide bridge to the Antennapedia domain vector peptide, which ensures rapid 
and effective uptake of the activator peptide. Once inside the cell, the disulfide bonds were 
subjected to reduction in the cytoplasm leading to release of the activator peptide. 
 
4.4.2. Cell proliferation 
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Preliminary experiments were conducted to assess cell viability, 6x105 cells/ml were treated with 
100 M of each compounds for 72 h. Cell viability was evaluated by assessing lactate 
dehydrogenase leakage using a commercially available kit (Takara Bio Inc., Japan), no cytotoxicity 
was observed (data not shown). Cells were seeded at a density of 6x105 cells/ml and incubated for 
72 h with five concentrations of the compounds (maximum concentration tested 100 M, and four 
1:5 dilutions) or DMSO as vehicle control. After incubation, cells were counted at the Coulter 
Counter (Coulter Electronics, Ltd., Luton, UK). From the dose response curve, the IC50 values (IC50 
= effective chemical concentration required to inhibit reduce to 50% cell proliferation compared to 
vehicle exposed cultures) for each compound was calculated by linear regression analysis of data.  
To assess the role of PKC on cell proliferation, 6x105 cells/ml were treated with increasing 
concentrations of Pseudo RACK for 72 h. After incubation, cells were counted at the Coulter 
Counter, results are expressed as number of cells x 106/ml. 
 
4.4.3. Cell cycle analysis by DNA content (propidium iodide, PI) 
After 72 h incubation, cells were centrifuged for 5 min at 1200 rpm at 5°C, culture media was 
discarded, cells washed with PBS, fixed overnight at -20°C in 70% ethanol in PBS. Cells were then 
centrifuged for 5 min at 1200 rpm at 5°C, washed once with cold PBS, and resuspended in 1 ml of 
PI/Triton X-100 staining solution. Samples were incubated at 30 minutes at 25°C protected from 
light, and acquired using a FACSCalibur flow cytometer and data were quantified using CellQuest 
software (Becton Dickinson). 30.000 events were analyzed to determine cellular distribution in 
different phases of the cell cycle. Results are expressed as % of cells.[38] 
 
4.4.4. Western blot analysis 
For western blot analysis, after 48 h incubation, cells were centrifuged for 5 min at 1200 rpm at 5°C, 
culture media was discarded, cells washed with PBS. The supernatant was discarded, and cells 
lysed in 100 μl of homogenization buffer (50 mM TRIS, 150 mM NaCl, 5 mM EDTA pH 7.5, 0.5% 
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Triton X-100, 50 μM PMSF, 2 μg/mL aprotinin, 1 μg/mL pepstatin and 1 μg/mL leupeptin). 100 μl 
of sample buffer 2X (125 Mm Tris HCl pH 6.8, 4% SDS, 20% glycerol, bromophenol blue, 6% β-
mercaptoethanol) were added and samples denatured for 10 min at 100°C. Protein content was 
assessed using a commercial kit (Bio-Rad, Hercules, CA, USA). Twenty micrograms of proteins 
were electrophoresed into a 10% sodium dodecyl sulfate (SDS)–polyacrylamide gel under reducing 
condition. The proteins were then transferred to polyvinylidene difluoride (PVDF) membrane 
(Amersham, Little Chalfont, UK). Proteins were visualized using as primary antibodies against 
PKCα, PKCβII and RACK1, and developed using enhanced chemiluminescence (Bio-Rad). The 
images of the blots were acquired with the Molecular Imager Gel Doc XR (Bio-Rad). Optical 
density (OD) of bands was calculated and analyzed by means of the Image Lab version 4.0.1 (Bio-
Rad), normalized by -tubulin, and results expressed as percentage of control. 
 
4.4.5. Statistical analysis 
All experiments were repeated at least three times. Data are expressed as mean ± SD. Statistical 
analysis was performed using InStat software version 7.0 (GraphPad Software, La Jolla, CA, USA). 
Statistical significance was determined by ANOVA followed by a multiple comparison test as 
indicated in the legends. Effects were designated significant at p<0.05. 
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